



## Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference

November 7, 2023

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Nov. 7, 2023-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the 2023 Jefferies London Healthcare Conference being held from November 14-16, 2023 in London.

Details of the event are as follows:

Date: Tuesday, November 14, 2023

Time: 5:00 p.m. BST

The live audio webcast of the presentation can be accessed on the Investors section of Adicet Bio's website at <http://www.adicetbio.com>. An archived replay will be available for 30 days following the presentation.

### About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAAs), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at <https://www.adicetbio.com>.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20231107487145/en/>

### Adicet Bio., Inc.

#### Investor and Media Contacts

Anne Bowdidge

[abowdidge@adicetbio.com](mailto:abowdidge@adicetbio.com)

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

[janhavi.mohite@sternir.com](mailto:janhavi.mohite@sternir.com)

Source: Adicet Bio, Inc.